iOnctura
iOnctura develops precision oral small-molecule therapies targeting challenging cancers by intervening in tumor-stroma-immune biology. Its pipeline includes roginolisib (IOA-244), Cambritaxestat (IOA-289), and IOA-359.
0 jobs
Jobs
No jobs match — try clearing a filter.